Talk:Allergan

FML Forte (0.25%) OPHTH SUSP 5ML

I have found that the FML Forte eye drop used to used to treat eye PRK and Lasik post operative side affects is at least 10 drops short on the first two bottles that I purchased from Allergan Pharmaceuticals. It is $250.00 U.S. dollars per bottle. They use the metric conversion table to fill their bottles which their Quality Assurance Section stated was 15 drops per ML. It is actually suppose to be 15.4 drops per ML using the metric table. The U.S. conversion table is 20 drops per ML. If you call their Quality Assurance Section they will say they put extra drops in each bottle. They will of course deny that their bottles are short any drops. PRK and Lasik is a very popular eye corrective surgery in the United States. Allergan Stock is $223.00 per share. — Preceding unsigned comment added by 75.71.10.154 (talk) 15:09, 26 April 2016 (UTC)

Interesting, and quite factual analysis that should be further pursued.--Wikipietime (talk) 15:32, 9 September 2017 (UTC)

Proposed merge with Naurex

stub, was bought by Allergan. Natureium (talk) 20:45, 26 January 2017 (UTC)

Intellectual property and patent transfer to St. Regis Mohawk Reservation

St. Regis Mohawk Reservation has come online for protection of ip.

Casinos Aren’t Enough as Native Tribe Makes Deal on Drug Patents

https://www.bloomberg.com/news/articles/2017-09-09/casinos-aren-t-enough-as-native-tribe-makes-deal-on-drug-patents

--Wikipietime (talk) 15:30, 9 September 2017 (UTC)

Edit request to add sources to "Key products" section

On behalf of Allergan, and as part of my work at Beutler Ink, I am looking to make some updates and improvements to this Wikipedia article. I'd like to start with a very straightforward request. Currently, the "Key products" section is almost entirely unsourced. There are two inline citations in the section, both of which direct readers to the Allergan website, and I think we can all agree this is not ideal. I've found sources to verify connections between Allergan and each of the products currently listed in this section. I believe they are appropriate for Wikipedia, and I've not made other major content changes. I'm merely attempting to improve the article's integrity by adding sourcing. Below, I offer a rendering of an updated "Key products" section and markup for editor review:

Rendering of proposed "Key products" section

Actonel (risedronic acid) for the treatment or prevention osteoporosis, and for Paget's disease of bone treatment Acuvail (ketorolac ophthalmic solution) for the treatment of pain and inflammation following cataract surgery Aczone (dapsone gel) for acne Alphagan P (brimonidine ophthalmic solution) for glaucoma Androderm CIII (testosterone transdermal system) for replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone Asacol HD (mesalamine extended release) for moderately active ulcerative colitis Atelvia (risedronic acid delayed release) for the treatment of osteoporosis in postmenopausal women Avycaz (ceftazidime/avibactam) for complicated intra-abdominal infections (in combination with metronidazole) Botox (onabotulinumtoxinA) for various spasms and dystonias Botox Cosmetic/Vistabel (onabotulinumtoxinA), an anti-wrinkle cosmetic drug derived from Botox Bystolic (nebivolol) for hypertension Combigan (brimonidine/timolol) for glaucoma Crinone (progesterone gel) for progesterone supplementation or replacement as part of an assisted reproductive technology (ART) treatment for infertile women with progesterone deficiency Dalvance (dalbavancin) for acute bacterial skin and skin structure infections (ABSSSI) Delzicol (mesalamine extended release) for mildly-to-moderately active ulcerative colitis Doryx (doxycycline hyclate extended release), a tetracycline-class antimicrobial Enablex (darifenacin extended release) for overactive bladder Estrace (estradiol vaginal cream) for vulvar and vaginal atrophy due to menopause Fetzima (levomilnacipran extended release) for major depressive disorder Gelnique (oxybutynin gel) for overactive bladder Juvéderm injectable gel (cross-linked hyaluronic acid), a dermal filler Kybella (deoxycholic acid injection) for double chin Lastacaft (alcaftadine ophthalmic solution) for the prevention of itching associated with eye allergies Latisse (bimatoprost ophthalmic solution) for hypotrichosis of the eyelashes Liletta (levonorgestrel-releasing intrauterine system) for contraception Linzess (linaclotide) for irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation—co-marketed with Ironwood Pharmaceuticals Lo Loestrin Fe (norethisterone and ethinylestradiol; ethinylestradiol; ferrous fumarate) for contraception Lumigan (bimatoprost ophthalmic solution) for glaucoma Namenda (memantine) for moderate-to-severe dementia of the Alzheimer's type Namenda XR (memantine extended release) for moderate-to-severe Alzheimer's disease Namzaric (memantine extended release/donepezil) for moderate-to severe-Alzheimer's disease in patients who are currently taking and can continue to take certain doses of both Namenda or Namenda XR (see above) and donepezil Natrelle breast implants (silicone and saline) Optive (carboxymethyl cellulose eye drops) - prescribed for patients who have undergone LASIK to prevent dryness of the eyes Ozurdex (dexamethasone intravitreal implant) for branch retinal vein occlusion (BRVO) and central retinal vein occlusion (CRVO) Orbera system—an intragastric balloon, inserted endoscopically; designed to assist weight loss by partially filling the stomach and inducing satiety for overweight patients with a body mass index (BMI) of 27 or greater Rapaflo (silodosin) for benign prostatic hyperplasia Restasis (ciclosporin ophthalmic emulsion) for dry eye syndrome Saphris (asenapine sublingual tablets) for schizophrenia and bipolar I disorder Skinmedica for facial lines Tazorac (tazarotene) for acne and psoriasis Teflaro (ceftaroline fosamil) for community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI) Viberzi (eluxadoline) for diarrhea-predominant irritable bowel syndrome (IBS-D) Viibryd (vilazodone) for major depressive disorder Zenpep (pancrelipase) for the treatment of exocrine pancreatic insufficiency due to cystic fibrosis, or other conditions.

References
References

Markup

{{columns-list|colwidth=30em| * Actonel ([[risedronic acid]]) for the treatment or prevention osteoporosis, and for [[Paget's disease of bone]] treatment<ref>{{Cite news|url=https://www.reuters.com/article/us-allergan-m-a-teva-pharm-ind/teva-says-allergan-deal-to-close-any-time-expects-u-s-antitrust-clearance-idUSKCN0ZT1EX|title=Teva says Allergan deal to close 'any time', expects U.S. antitrust clearance|date=July 13, 2016|accessdate=January 12, 2018|first1=Caroline|last1=Humer|first2=Tova|last2=Cohen|publisher=[[Reuters]]}}</ref> * Acuvail ([[ketorolac]] ophthalmic solution) for the treatment of pain and inflammation following [[cataract surgery]]<ref>{{Cite web|url=https://www.dddmag.com/news/2009/07/allergan-receives-fda-approval-acuvail|title=Allergan Receives FDA Approval for Acuvail|date=July 24, 2009|website=Drug Discovery and Development|publisher=Advantage Business Media|accessdate=January 12, 2018|via=[[Associated Press]]}}</ref> * Aczone ([[dapsone]] gel) for acne<ref>{{Cite news|url=https://www.reuters.com/article/us-allergan/allergan-to-buy-qlts-acne-gel-for-150-mln-idUSN0933735620080609|title=Allergan to buy QLT's acne gel for $150 mln|date=June 9, 2008|first=Lewis|last=Krauskopf|publisher=Reuters|accessdate=January 12, 2018}}</ref> * Alphagan P ([[brimonidine]] ophthalmic solution) for glaucoma<ref>{{Cite journal|url=https://www.forbes.com/2005/08/22/allergan-alcon-pharmaceuticals-0822markets16.html#5c406c9f309d|date=August 22, 2005|work=[[Forbes]]|accessdate=January 12, 2018|title=Allergan Bolsters Generic Defense Strategy|issn=0015-6914}}</ref> * Androderm CIII ([[testosterone (medication)|testosterone]] transdermal system) for replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone<ref>{{Cite news|url=http://www.renalandurologynews.com/androderm/drug/1114/|work=[[Renal & Urology News]]|publisher=[[Haymarket Media Group]]|issn=1550-9478|oclc=321350119|title=Androderm CIII|accessdate=January 12, 2018}}</ref> * Asacol HD ([[Mesalazine|mesalamine]] extended release) for moderately active [[ulcerative colitis]]<ref>{{Cite web|url=http://www.pharmacytimes.com/publications/issue/2016/september2016/generic-product-news-september-2016|title=Generic Product News (September 2016)|accessdate=January 12, 2018|date=September 22, 2016|work=Pharmacy Times|publisher=Pharmacy & Healthcare Communications}}</ref> * Atelvia ([[risedronic acid]] delayed release) for the treatment of osteoporosis in postmenopausal women<ref>{{Cite news|url=https://www.bloomberg.com/research/stocks/private/snapshot.asp?privcapId=695365|title=Company Overview of Warner Chilcott plc|accessdate=January 12, 2018|publisher=[[Bloomberg L.P.]]}}</ref> * Avycaz ([[ceftazidime/avibactam]]) for complicated intra-abdominal infections (in combination with [[metronidazole]])<ref>{{Cite news|url=http://www.pharmatimes.com/news/us_regulators_expand_use_of_allergans_antibiotic_1185496|title=US regulators expand use of Allergan's antibiotic|date=January 31, 2017|accessdate=January 12, 2018|work= PharmaTimes|first=Selina|last=McKee}}</ref> * [[Botox]] (onabotulinumtoxinA) for various [[spasm]]s and [[dystonia]]s<ref>{{Cite journal|url=https://www.newyorker.com/business/currency/actavis-allergan-botox-sale|first=Vauhini|last=Vara|date=November 18, 2014|accessdate=January 12, 2018|title=Billions and Billions for Botox|work=[[The New Yorker]]|publisher=[[Condé Nast]]|issn=0028-792X|oclc=320541675}}</ref> * Botox Cosmetic/Vistabel (onabotulinumtoxinA), an anti-[[wrinkle]] cosmetic drug derived from Botox<ref>{{cite book|title=Cosmetic Medicine and Surgery|date=January 27, 2017|publisher=[[CRC Press]]|url=https://books.google.com/books?id=vdMBDgAAQBAJ&pg=PT1395&lpg=PT1395&dq#v=onepage&q&f=false|accessdate=January 12, 2018|first1=Pierre|last1=Andre|first2=Eckart|last2=Haneke|first3=Leonardo|last3=Marini|first4=Christopher Rowland|last4=Payne}}</ref> * Bystolic ([[nebivolol]]) for [[hypertension]]<ref>{{Cite news|url=http://www.mcall.com/business/mc-brent-saunders-making-deals-at-allergan-20151017-story.html|title=Brent Saunders, Parkland grad, is the Lehigh Valley's $150 billion dealmaker|first=Jon|last=Harris|date=October 19, 2015|accessdate=January 12, 2018|work=[[The Morning Call]]|publisher=[[Tronc]]|location=Allentown, Pennsylvania}}</ref> * Combigan ([[brimonidine/timolol]]) for [[glaucoma]]<ref>{{Cite news|url=http://www.ocregister.com/2006/12/22/allergan-fda-seek-more-data-on-combigan/|title=Allergan: FDA Seek More Data on Combigan|date=December 22, 2006|work=[[Orange County Register]]|publisher=[[Digital First Media]]|issn=0886-4934|oclc=12199155|accessdate=January 12, 2018}}</ref> * Crinone ([[progesterone]] gel) for progesterone supplementation or replacement as part of an [[assisted reproductive technology]] (ART) treatment for [[Infertility|infertile]] women with progesterone deficiency<ref>{{Cite journal|url=https://www.bizjournals.com/boston/blog/bioflash/2015/10/the-most-successful-biotech-in-massachusetts.html|title= The most successful biotech in Massachusetts you've never heard of|accessdate=January 12, 2018|date=October 28, 2015|first=Don|last=Seiffert|work=[[Boston Business Journal]]|publisher=[[American City Business Journals]]|issn=0746-4975}}</ref> * Dalvance ([[dalbavancin]]) for acute bacterial [[skin and skin structure infection]]s (ABSSSI)<ref>{{Cite news|url=http://www.pharmacytimes.com/product-news/single-dose-treatment-option-approved-for-skin-infection-drug-dalvance|title=Single-Dose Treatment Option Approved for Skin Infection Drug Dalvance|date=January 28, 2016|accessdate=January 12, 2018|first=Krystle|last=Vermes|website=Pharmacy Times}}</ref> * Delzicol ([[Mesalazine|mesalamine]] extended release) for mildly-to-moderately active [[ulcerative colitis]]<ref>{{Cite news|url=http://www.thehindubusinessline.com/companies/zydus-settles-patent-litigation-of-allergans-delzicol-drug/article9408915.ece?ref=relatedNews|title=Zydus settles patent litigation of Allergan's Delzicol drug|date=December 3, 2016|work=[[Business Line]]|publisher=[[The Hindu Group]]|issn=0971-7528|oclc=456162874|accessdate=January 12, 2018}}</ref> * Doryx ([[doxycycline]] hyclate extended release), a tetracycline-class antimicrobial<ref>{{Cite news|url=http://www.smh.com.au/business/mayne-pays-up-for-full-control-of-acne-treatment-20150210-13aib0.html|title=Mayne pays up for full control of acne treatment|date=February 10, 2015|accessdate=January 12, 2018|first=Brian|last=Robins|work=[[The Sydney Morning Herald]]|publisher=[[Fairfax Media]]|issn=0312-6315|oclc=226369741}}</ref> * Enablex ([[darifenacin]] extended release) for [[overactive bladder]]<ref>{{Cite news|url=https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/cipla-gets-usfda-nod-for-overactive-bladder-treating-drug/articleshow/53979990.cms|title=Cipla gets USFDA nod for overactive bladder treating drug|date=September 2, 2016|accessdate=January 12, 2018|work=[[The Economic Times]]|publisher=[[The Times Group]]|oclc=61311680}}</ref> * Estrace ([[estradiol]] vaginal cream) for [[Atrophic vaginitis|vulvar and vaginal atrophy]] due to [[menopause]]<ref>{{Cite news|url=https://www.thestreet.com/story/14003652/1/5-nbsp-ways-allergan-can-keep-up-momentum.html|title=5 Ways Allergan Can Keep Up Momentum|date=February 15, 2017|accessdate=January 12, 2018|first=Robert|last=Wasserman|work=[[TheStreet.com]]}}</ref><ref>{{Cite book|url=https://books.google.com/books?id=FLGMDgAAQBAJ&pg=PA129&lpg=PA129&dq#v=onepage&q&f=false|page=129|title=Complications of Female Incontinence and Pelvic Reconstructive Surgery|first=Howard B.|last=Goldman|publisher=Humana Press|date=March 28, 2017|accessdate=January 12, 2018}}</ref> * Fetzima ([[levomilnacipran]] extended release) for [[major depressive disorder]]<ref>{{Cite news|url=https://motherboard.vice.com/en_us/article/7xxyxd/prescription-drug-side-effects-disability|title=When Should a Prescription Drug's Side Effects Count as a Disability?|first=Sarah|last=Scoles|date=September 11, 2017|accessdate=January 12, 2018|work=[[Vice (magazine)|Vice]]|publisher=[[Vice Media]]|issn=1077-6788|oclc=30856250}}</ref> * Gelnique ([[oxybutynin]] gel) for overactive bladder<ref>{{Cite journal|url=https://www.bizjournals.com/philadelphia/news/2017/02/09/antares-goal-5-product-approvals-over-next-two.html|title=Antares' goal: 5 product approvals over next two years|first=John|last=George|date=February 9, 2017|accessdate=January 12, 2018|work=[[Philadelphia Business Journal]]|publisher=American City Business Journals|issn=0744-3587}}</ref> * [[Juvéderm]] injectable gel (cross-linked [[hyaluronic acid]]), a dermal filler<ref>{{Cite journal|url=https://www.ocbj.com/news/2017/aug/03/allergan-2q-strong-raises-guidance-performance/|title=Allergan Q2 Strong, Raises Guidance|date=August 3, 2017|accessdate=January 12, 2018|first=Sherry|last=Hsieh|work=[[Orange County Business Journal]]}}</ref> * Kybella ([[deoxycholic acid]] injection) for double chin<ref>{{Cite journal|url=https://www.theatlantic.com/health/archive/2017/06/kybella-the-injection-that-melts-a-double-chin/529893/|title=The Injection That Melts a Double Chin|first=Lindsey Hunter|last=Lopoz|date=June 14, 2017|accessdate=January 12, 2018|work=[[The Atlantic]]|issn=1072-7825}}</ref> * Lastacaft ([[alcaftadine]] ophthalmic solution) for the prevention of itching associated with eye allergies<ref>{{Cite web|url=https://www.reviewofophthalmology.com/article/lastacaft-takes-allergan-back-to-its-roots-26704|title=Lastacaft Takes Allergan Back to its Roots|date=February 15, 2011|accessdate=January 12, 2018|website=Review of Ophthalmology}}</ref> * Latisse ([[bimatoprost]] ophthalmic solution) for [[hypotrichosis]] of the eyelashes<ref>{{Cite news|url=http://abcnews.go.com/Health/story?id=6544525|title=Lash-Lengthener Latisse Is Glaucoma Drug Lumigan's Second Life|date=December 29, 2008|first=Radha|last=Chitale|publisher=[[ABC News]]|accessdate=January 12, 2018}}</ref> * Liletta ([[levonorgestrel]]-releasing intrauterine system) for [[contraception]]<ref>{{Cite journal|url=https://www.wired.com/story/liletta-the-iud-that-gives-women-options/|title=The IUD That Gives Women Options|date=August 25, 2017|first=Menaka|last=Wilhelm|work=[[Wired (magazine)|Wired]]|publisher=Condé Nast|issn=1059-1028|oclc=24479723}}</ref> * Linzess ([[linaclotide]]) for [[irritable bowel syndrome]] with constipation (IBS-C) and [[Functional constipation|chronic idiopathic constipation]]—co-marketed with [[Ironwood Pharmaceuticals]]<ref>{{Cite news|url=http://www.pharmacytimes.com/product-news/fda-approves-new-dose-for-chronic-idiopathic-constipation-drug|work=Pharmacy Times|title=FDA Approves New Dose for Chronic Idiopathic Constipation Drug|date=January 27, 2017|first=Jennifer|last=Barrett|accessdate=January 12, 2018}}</ref> * Lo Loestrin Fe ([[norethisterone]] and [[ethinylestradiol]]; ethinylestradiol; ferrous fumarate) for contraception<ref>{{Cite journal|url=https://www.prweek.com/article/1448727/allergan-easing-conversation-birth-control|title=How Allergan is easing the conversation about birth control|date=November 1, 2017|first=Alison|last=Kanski|work=[[PRWeek]]|publisher=Haymarket Media}}</ref> * Lumigan ([[bimatoprost]] ophthalmic solution) for [[glaucoma]]<ref>{{Cite news|url=https://www.reuters.com/article/us-aerie-glaucoma-fda/aeries-glaucoma-drug-effectively-lowers-eye-pressure-fda-review-idUSKBN1CG1O4|publisher=Reuters|title=Aerie's glaucoma drug effectively lowers eye pressure: FDA review|date=October 11, 2017|accessdate=January 12, 2018|first=Toni|last=Clarke}}</ref> * Namenda ([[memantine]]) for moderate-to-severe [[Alzheimer's disease|dementia of the Alzheimer's type]]<ref>{{Cite news|url=https://www.bloomberg.com/news/articles/2017-01-19/allergan-focuses-on-alzheimer-s-symptoms-as-treatment-eludes|title=Allergan Focuses on Alzheimer’s Symptoms as Treatment Eludes|first=Jared S.|last=Hopkins|date=January 19, 2017|publisher=Bloomberg L.P.|accessdate=January 12, 2018}}</ref> * Namenda XR (memantine extended release) for moderate-to-severe Alzheimer's disease<ref name=Blocking>{{Cite news|url=https://www.reuters.com/article/allergan-lawsuit/allergan-drops-appeal-of-order-blocking-alzheimers-drug-switch-idUSL1N13K1J120151125|title=Allergan drops appeal of order blocking Alzheimer's drug switch|accessdate=January 12, 2018|date=November 25, 2015|first=Brendan|last=Pierson|publisher=Reuters}}</ref> * Namzaric ([[memantine]] extended release/[[donepezil]]) for moderate-to severe-Alzheimer's disease in patients who are currently taking and can continue to take certain doses of both Namenda or Namenda XR (see above) and donepezil<ref name=Blocking/> * Natrelle [[breast implant]]s (silicone and saline)<ref>{{Cite news|url=https://www.cbsnews.com/news/fda-approves-new-gummy-bear-silicone-breast-implant/|title=FDA approves new "Gummy Bear" silicone breast implant|first=Ryan|last=Jaslow|date=February 25, 2013|accessdate=January 12, 2018|publisher=[[CBS News]]}}</ref> * Optive ([[carboxymethyl cellulose]] eye drops) - prescribed for patients who have undergone [[LASIK]] to prevent dryness of the eyes<ref>{{cite web|url=http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/news/user-defined-tags/allergan/allergan-launches-preservative-free-drops|title= Allergan launches preservative-free drops|date=February 20, 2013|accessdate=January 12, 2018}}</ref> * Ozurdex ([[dexamethasone]] intravitreal implant) for [[branch retinal vein occlusion]] (BRVO) and [[central retinal vein occlusion]] (CRVO)<ref>{{Cite web|url=https://www.aop.org.uk/ot/professional-support/health-services/2017/06/07/ozurdex-receives-nice-fad-recommendation-for-uveitis-use|title= Ozurdex Receives Nice FAD Recommendation for Uveitis Use|publisher=[[Association of Optometrists]]|work=Optometry Today|accessdate=January 12, 2018|date=June 7, 2017|first=Emily|last=McCormick}}</ref> * Orbera system—an intragastric balloon, inserted endoscopically; designed to assist weight loss by partially filling the stomach and inducing satiety for overweight patients with a [[body mass index]] (BMI) of 27 or greater<ref>{{Cite news|url=https://www.theglobeandmail.com/life/health-and-fitness/gastric-balloon-offers-weight-loss-hope/article4327646/|title=Gastric balloon offers weight loss hope|first=Tralee|last=Pearce|date=September 29, 2010|accessdate=January 12, 2018|work=[[The Globe and Mail]]|publisher=[[The Woodbridge Company]]|issn=0319-0714}}</ref> * Rapaflo ([[silodosin]]) for [[benign prostatic hyperplasia]]<ref>{{Cite news|url=http://www.thehindu.com/business/Lupin-receives-USFDA-nod-for-anti-bacterial-tablets/article14625018.ece|title=Lupin receives USFDA nod for anti-bacterial tablets|date=September 6, 2016|accessdate=January 12, 2018|work=[[The Hindu]]|issn=0971-751X|oclc=13119119}}</ref> * Restasis ([[ciclosporin]] ophthalmic emulsion) for [[Keratoconjunctivitis sicca|dry eye syndrome]]<ref>{{Cite news|url=https://www.ft.com/content/5ec7305a-9f17-11e7-9a86-4d5a475ba4c5|title=Allergan deal with Mohawk tribe casts patent shadow|accessdate=January 12, 2018|work=[[Financial Times]]|issn=0307-1766}}</ref> * Saphris ([[asenapine]] sublingual tablets) for [[schizophrenia]] and [[bipolar I disorder]]<ref>{{Cite news|url=https://www.reuters.com/article/health-saphris/judge-upholds-patent-on-allergans-schizophrenia-drug-saphris-idUSL1N1JS00R|title=Judge upholds patent on Allergan's schizophrenia drug Saphris|first=Brendan|last=Pierson|date=June 30, 2017|accessdate=January 12, 2018|publisher=Reuters}}</ref> * Skinmedica for facial lines<ref>{{Cite news|url=http://www.ocregister.com/2012/12/20/allergan-buys-skinmedica-for-350-million/|title=Allergan buys SkinMedica for $350 million|first=Kevin|last=Sablan|date=December 20, 2012|accessdate=January 12, 2018|work=Orange County Register}}</ref> * Tazorac ([[tazarotene]]) for [[acne]] and [[psoriasis]]<ref>{{Cite book|url=https://books.google.com/books?id=mbEBAEAaOKgC&pg=PA111&lpg=PA111&dq#v=onepage&q&f=false|page=111|title=Retinoids and Carotenoids in Dermatology|publisher=CRC Press|first1=Anders|last1=Vahlquist|first2=Madeleine|last2=Duvic|date=June 20, 2007}}</ref> * Teflaro ([[ceftaroline fosamil]]) for [[Community-acquired pneumonia|community-acquired bacterial pneumonia]] (CABP) and acute bacterial skin and skin structure infections (ABSSSI)<ref>{{Cite news|url=https://www.reuters.com/article/idUSFWN18S09V|title=Brief: Allergan receives FDA approval of Teflaro|publisher=Reuters|accessdate=January 12, 2018|date=May 31, 2018}}</ref> * Viberzi ([[eluxadoline]]) for diarrhea-predominant [[irritable bowel syndrome]] (IBS-D)<ref>{{Cite news|url=https://www.mediapost.com/publications/article/272794/allergan-launches-campaign-for-viberzi.html|title=Allergan Launches Campaign For Viberzi|accessdate=January 12, 2018|date=April 5, 2016|first=Nina|last=Lentini|work=Marketing Daily|publisher=[[MediaPost Communications]]}}</ref> * Viibryd ([[vilazodone]]) for [[major depressive disorder]]<ref>{{Cite news|url=https://www.reuters.com/article/us-allergan-fda/allergan-gets-fda-nod-for-new-antipsychotic-idUSKCN0RH2PS20150917|title=Allergan gets FDA nod for new antipsychotic|date=September 17, 2015|first=Vidya L.|last=Nathan|publisher=Reuters|accessdate=January 12, 2018}}</ref> * Zenpep ([[pancrelipase]]) for the treatment of [[exocrine pancreatic insufficiency]] due to [[cystic fibrosis]], or other conditions.<ref>{{Cite news|url=http://www.pmlive.com/pharma_news/allergan_eyes_early_2017_european_launch_for_enzepi_1014016|title=Allergan eyes early 2017 European launch for Enzepi|date=May 3, 2016|accessdate=January 12, 2018|first=Rebecca|last=Clifford|work=PMLive.com|publisher=PMGroup Worldwide}}</ref> }}

I'm seeking a volunteer to review the proposed markup and copy over appropriately. Happy to answer any questions here or on my user talk page. Thanks! Inkian Jason (talk) 20:16, 12 January 2018 (UTC)

I just removed the section, per WP:NOTCATALOG. The section above would still violate that policy. Jytdog (talk) 23:39, 12 January 2018 (UTC)

@Jytdog: Thanks for reviewing this request. I would think an overview of the company's products would be helpful, and my goal here was merely to source unsourced content. While I don't have any problem with your edit to the article, I am curious, would an overview of the company's products in another format be helpful? Inkian Jason (talk) 21:42, 16 January 2018 (UTC)

nope, per WP:NOTCATALOG. Jytdog (talk) 00:12, 17 January 2018 (UTC)

@Jytdog: I realized I didn't follow up here, apologies for that. While a listing of products is understandably not appropriate, I assume the article should mention something about the products in non-listing, prose form. I'm working on a draft that will do this and will work to ensure it meets guidelines. For now, a short mention of just the notable products is included in the proposed Corporate overview section below to illustrate the type of products that the company produces. Inkian Jason (talk) 20:55, 1 March 2018 (UTC)

Infobox requests

Hello! I am back with an additional edit request, which I am submitting on behalf of Allergan as part of my work at Beutler Ink. For this request, I propose three specific updates to the article's infobox:

1. Changing the "Industry" field to simply "Healthcare": "Branded and generic pharmaceuticals, and pharmaceutical research and development" are too specific and seem more appropriate for a products/services field. Allergan offers other pharmaceutical services and devices, so "Healthcare" is more encompassing. Not to mention, the current "Products" field already says "Branded and generic pharmaceuticals", which seems redundant.
2. Changing the "Founder" field: Currently, the infobox displays, "Allen Chao, Ph.D. and David Hsia, Ph.D." I propose including "Gavin Herbert", per this source, which says, "Gavin Herbert founded Allergan Inc. above his father’s drugstore in 1948. The company is now known as Allergan Plc, with international headquarters in Dublin and $15 billion in annual revenue." Should the founders of both Actavis and Allergan Inc. be included? I seek input from volunteer editors about how to best approach this.
3. Updating the financial parameters and number of employees: Currently, the "Revenue" parameter displays 2016 information. I propose using this same source to display 2016 information for the other parameters, too. This would mean changing the "net income" field to "US$ 14.695 billion (2016)", the "total assets" field to "US$ 128.986 billion (2016)", and the "total equity" field to "US$ 76.2 billion (2016)" (see pg. 48). If we're continuing with 2016 details, the "number of employees" field can be updated from "30,000 (June 2015)" to "16,700 (2016)" (see pg. 22).

I will have additional requests for updating and improving this article, but this request is enough for volunteer editors to review for now. Please let me know if you have any questions. Thank you! Inkian Jason (talk) 21:38, 1 February 2018 (UTC)

Reply 1-FEB-2018

Partially implemented

1. The industry title remains, as their primary focus in heathcare is therapeutics.
2. Gavin Herbert founded Allergan, Inc. and had nothing to do with Allergan, which formed just recently. They share only the name, not the legacy.
3. Certain financials were updated; others, such as operating income, were not.
4. Employee number was updated.

Regards, Spintendo ᔦᔭ 00:13, 2 February 2018 (UTC)

Thank you for your help, User:Spintendo, and for updating the infobox. The relationship between Actavis, Allergan Inc. and Allergan PLC (the subject of this article) is definitely not the clearest it could be in this article. I'm working with my contact to understand that better and hopefully offer some more updates soon. Meantime, please note that that the entries for Allen Chao and David Hsia are currently unsourced, and their names do not appear elsewhere in the article's prose. Furthermore, Allen Chao's Wikipedia article does not mention Allergan or Actavis. I hope you'll reconsider removing their names from the infobox. Inkian Jason (talk) 21:07, 2 February 2018 (UTC)

 Done Spintendo ᔦᔭ 02:20, 3 February 2018 (UTC)

@Spintendo: Thank you. One quick correction to your changes: The employee number statistic is for 2016, not June 2015. Do you mind making this correction? Inkian Jason (talk) 20:03, 5 February 2018 (UTC)

Another editor corrected the date with this edit. Inkian Jason (talk) 16:17, 15 February 2018 (UTC)

Proposed "Corporate overview" section

I am back with an additional request, which I am submitting on behalf of Allergan as part of my work at Beutler Ink.

Currently, this article jumps straight into a complicated, six-sectioned corporate history. I think the article could benefit from starting with a "Corporate overview" section, providing a snapshot of the company before diving right into history details. Based on similar overview sections for company articles, I propose the following, which includes mention of the company's formation, headquarters (and second major operations hub), the number of employees and revenue for 2016, the name of the current chief executive, and a brief summary of Allergan's products and business model:

Extended content

Corporate overview Allergan was created in 2015 when the company formerly known as Actavis, Plc acquired Allergan, Inc. and continued to use Allergan's name. Allergan is based in Dublin and has major operations in Irvine. In 2016, the company had 16,700 employees and earned $14.57 billion. Brent Saunders serves as Allergan's chief executive officer (CEO). In 2015, prior to Teva Pharmaceutical Industries' purchase of the company's generic drugs business, Allergan offered approximately 1,000 products, including branded generics, over-the-counter drugs, and generic forms of popular pharmaceutical drugs. Since the sale of Allergan Generics, the company has focused on branded pharmaceuticals. Some of the company's products include: Avycaz, Botox CoolSculpting, Dalvance, Juvéderm, Linzess, Viberzi, and Vraylar.

References
References

Markup

==Corporate overview== Allergan was created in 2015 when the company formerly known as [[Actavis|Actavis, Plc]] acquired [[Allergan, Inc.]] and continued to use Allergan's name.<ref>{{cite news|url=https://www.wsj.com/articles/actavis-earnings-soar-as-closing-of-allergan-deal-looms-1424260951|title=Actavis Adopting Allergan Name; Earnings Soar as Closing of Deal Looms |work=The Wall Street Journal|date=18 February 2015|accessdate=19 February 2015|first=Michael|last=Calia}}</ref><ref>{{cite news|url=https://www.wsj.com/articles/actavis-changes-name-to-allergan-after-deal-for-botox-maker-1434370774|title=Actavis Changes Name to Allergan After Deal for Botox Maker|work=The Wall Street Journal|date=15 June 2015|accessdate=15 June 2015|first=Neil|last=Haggerty}}</ref> Allergan is based in Dublin and has major operations in Irvine.<ref name=ToBuy/><ref name=Biggest>{{cite news|url=http://www.latimes.com/business/la-fi-allergan-pfizer-20151029-story.html|accessdate=14 December 2017|work=[[Los Angeles Times]]|publisher=[[Tronc]]|issn=0458-3035|oclc=3638237|title=An Allergan-Pfizer deal could be biggest merger this year|date=October 29, 2015|first1=James F.|last1=Peltz|first2=Samantha|last2=Masunaga}}</ref> In 2016, the company had 16,700 employees and earned $14.57 billion.<ref name=SEC/> [[Brenton L. Saunders|Brent Saunders]] serves as Allergan's [[chief executive officer]] (CEO).<ref name="Scrap">{{cite news|title=Pfizer, Allergan scrap $160 billion deal after U.S. tax rule change|url=https://www.reuters.com/article/us-allergan-m-a-pfizer/pfizer-allergan-scrap-160-billion-deal-after-u-s-tax-rule-change-idUSKCN0X3188|accessdate=13 December 2017|publisher=[[Reuters]]|date=6 April 2016|first1=Caroline|last1=Humer|first2=Ankur|last2=Banerjee}}</ref> In 2015, prior to [[Teva Pharmaceutical Industries]]' purchase of the company's [[generic drug]]s business, Allergan offered approximately 1,000 products, including branded generics, [[over-the-counter drugs]], and generic forms of popular [[pharmaceutical drug]]s.<ref name="ToBuy">{{cite news|title=Teva to Buy Allergan Generics for $40.5 Billion|url=https://www.wsj.com/articles/teva-to-buy-allergan-generics-for-40-5-billion-1437988044|accessdate=14 December 2017|work=[[The Wall Street Journal]]|date=27 July 2015|first1=Jonathan D.|last1=Rockoff|first2=Dana|last2=Mattioli|first3=Liz|last3=Hoffman|publisher=[[News Corp]] ([[Dow Jones & Company]])|issn=0099-9660|oclc=781541372}}</ref> Since the sale of Allergan Generics, the company has focused on branded pharmaceuticals.<ref name=ToBuy/> Some of the company's products include: [[Ceftazidime/avibactam|Avycaz]],<ref>{{Cite news|url=http://www.pharmatimes.com/news/us_regulators_expand_use_of_allergans_antibiotic_1185496|title=US regulators expand use of Allergan's antibiotic|date=31 January 2017|accessdate=12 January 2018|work= PharmaTimes|first=Selina|last=McKee}}</ref> [[Botox]]<ref>{{Cite journal|url=https://www.newyorker.com/business/currency/actavis-allergan-botox-sale|first=Vauhini|last=Vara|date=18 November 2014|accessdate=12 January 2018|title=Billions and Billions for Botox|work=[[The New Yorker]]|publisher=[[Condé Nast]]|issn=0028-792X|oclc=320541675}}</ref> [[Cryolipolysis|CoolSculpting]],<ref>{{cite news|title=Allergan is buying CoolSculpting provider Zeltiq for $2.48 billion|url=http://www.latimes.com/business/la-fi-allergan-zeltiq-coolsculpting-20170213-story.html|accessdate=25 January 2018|work=Los Angeles Times|date=13 February 2017}}</ref> [[Dalbavancin|Dalvance]],<ref>{{Cite news|url=http://www.pharmacytimes.com/product-news/single-dose-treatment-option-approved-for-skin-infection-drug-dalvance|title=Single-Dose Treatment Option Approved for Skin Infection Drug Dalvance|date=28 January 2016|accessdate=12 January 2018|first=Krystle|last=Vermes|website=Pharmacy Times}}</ref> [[Juvéderm]],<ref>{{Cite journal|url=https://www.ocbj.com/news/2017/aug/03/allergan-2q-strong-raises-guidance-performance/|title=Allergan Q2 Strong, Raises Guidance|date=3 August 2017|accessdate=12 January 2018|first=Sherry|last=Hsieh|work=[[Orange County Business Journal]]}}</ref> [[Linaclotide|Linzess]],<ref>{{Cite news|url=http://www.pharmacytimes.com/product-news/fda-approves-new-dose-for-chronic-idiopathic-constipation-drug|work=Pharmacy Times|title=FDA Approves New Dose for Chronic Idiopathic Constipation Drug|date=27 January 2017|first=Jennifer|last=Barrett|accessdate=12 January 2018}}</ref> [[Eluxadoline|Viberzi]],<ref>{{Cite news|url=https://www.mediapost.com/publications/article/272794/allergan-launches-campaign-for-viberzi.html|title=Allergan Launches Campaign For Viberzi|accessdate=12 January 2018|date=5 April 2016|first=Nina|last=Lentini|work=Marketing Daily|publisher=[[MediaPost Communications]]}}</ref> and [[Cariprazine|Vraylar]].<ref>{{cite news|title=Brief: Allergan receives FDA approval for use of Vraylar in maintenance treatment of schizophrenia|url=https://www.reuters.com/article/brief-allergan-receives-fda-approval-for/brief-allergan-receives-fda-approval-for-use-of-vraylar-in-maintenance-treatment-of-schizophrenia-idUSASB0BTG0|accessdate=25 January 2018|publisher=Reuters|date=12 November 2017}}</ref>

I don't think these claims are very controversial to include, not to mention they help verify some of the (currently unsourced) content displayed in the article's infobox. Note: The SEC citation included in the rendering and markup above, which I included for easier editor review, is already used in the article. In order to avoid duplication, I suggest naming the SEC source and re-calling this citation within the proposed overview section.

I will not be editing the article directly given my conflict of interest, and I'm seeking help from neutral editors to review and implement this content appropriately. @XyZAn: I see you have made quite a few contributions to the article in the past, and have an interest in biotech and pharmaceutical companies. Would you consider taking a look at this proposed article improvement? I can address questions or concerns here, and thanks for any help in advance. Inkian Jason (talk) 17:01, 6 February 2018 (UTC)

@Inkian Jason: thanks for the tag, I will read this today/tomorrow and reply. Thanks XyZAn (talk) 18:05, 6 February 2018 (UTC)

@XyZAn: Great, thank you. Let me know if you have any questions. Inkian Jason (talk) 17:29, 12 February 2018 (UTC)

Hi again, I wanted to update and ping this request since I noticed that some problematic edits (as well as some helpful ones) have been made to the article within the last day (diff1 and diff2). Given these edits, I'd like to propose the following changes:

• Removing the recent History addition, and reverting back to the previous Corporate history section
• Reverting back to the previous version of the introduction, without the list of products
• Removing the listed owners in the infobox, since the company is publicly traded, and re-adding the previously existing (but poorly formatted) Ownership section

As well, I've taken this opportunity to revisit my proposed Corporate overview and have made a few adjustments, including removing products lacking Wikipedia articles (Botox Cosmetic/Vistabel, Botox Therapeutic, Lo Loestrin Fe, and Ozurdex), in order to keep focus on the most notable products. @XyZAn: Wanted to make sure you'd seen these recent edits and my update here in case you're still working on reviewing my request. Thanks, Inkian Jason (talk) 20:52, 1 March 2018 (UTC)

Move to Allergan plc

The formal name of Allergan is Allergan plc, which I propose this article title should be moved to. Allergan plc is the title the SEC gives Allergan on their 10=K, and also legally connects Allergan to being an Irish company (which it is). It also avoids confusion with the older Allergan, Inc. etc. Britishfinance (talk)